Predicting Risk and Guiding Care: Biomarkers & Genetic Testing in Prostate Cancer

The Contouring Assistant now marks Profound Medical’s second FDA-cleared TULSA-AI module.

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

Investigators will begin setting up the TRANSFORM trial in spring 2024, with study recruitment set to begin later in the year

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

All patients have been successfully dosed in the first cohort of patients, and the Safety Review Committee has granted approval for progression of the study to the second dose level of INKmune.

"I think in terms of the 2 large tool sets we have, biomarker testing through urine or blood tests and imaging. I think both are only going to get better," says Jeffrey Tosoian, MD, MPH.